This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
We know now that CLL patients who are fully vaccinated against COVID-19 are at higher risk for breakthrough infections, hospitalization, and death than the general public who are vaccinated. Boosters and prophylactic monoclonal antibodies are offering us new ways to improve our immunity.
COVID-19 Booster Newsflash Update!
On August 12, 2021, the FDA announced expanded Emergency Use Authorization (EUA) for a third booster dose of the Moderna or Pfizer vaccine for the immunocompromised. Between nine and ten million vulnerable patients, or 2.7% to 3% of the US population, will be eligible for the COVID-19 boosters. Please see Dr. Koffman’s helpful commentary here.
Additionally, CLL Society’s Official Statement on Boosters for CLL Patients, accessible here, is urging you not to wait to get the booster shot and can be shared with your healthcare team.
ASH 2020: Dr. Thomas Kipps on Frontline Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) with High-Risk Genomic Features. In this interview, Dr. Brian Koffman and Dr. Thomas Kipps discuss ibrutinib as a first-line therapy for high-risk CLL patients, as well as whether patients’ genetic mutations affect outcomes.
Upcoming CLL Society Virtual Events
CLL Society invites you to attend our August 26th webinar featuring Dr. Ian Flinn. Have you relapsed on, or become refractory to a BTKi drug such as ibrutinib, or the BCL-2i venetoclax? These drugs have radically improved how CLL is treated. However, when patients relapse or become refractory to these treatments, the approved PI3 kinase inhibitors duvelisib or idelalisib, and the still experimental umbralisib, offer a potent and potentially helpful third option. Side effects of PI3Ks have made some patients apprehensive. However, if properly managed, many CLL patients could reap benefits from these effective medications. Frontload your knowledge about PI3K inhibitors! Join us on August 26th for Revisiting PI3K Inhibitors for the Treatment of CLL: Are They Living Up to Their Promise? Send your questions in advance of the webinar by emailing firstname.lastname@example.org.
Do you want to brush up on your knowledge before the PI3K webinar? A second look at our previously published articles on this topic might help you to follow along or come up with questions.
- Things to Know About Idelalisib
- ASH 2019: Dr. Pagel Discusses Intermittent Dosing of PI3K Inhibitor ME401 in CLL
- ASH 2020: Dr. Davids Discusses Duvelisib and Venetoclax, an All-Oral Time-Limited Treatment for CLL
- ASH 2017: Dr. Brander on Umbralisib (TGR-1202) in CLL
Adding to last week’s suggested reading list, you may also want to take a look at these past articles on PI3 kinase inhibitors used in combinations before the August 26th webinar.
- ASH 2020: Dr. Jennifer Brown on Combination Duvelisib+Venetoclax for Patients with Relapsed/Refractory CLL
- ASH 2020: Dr. Paul Barr’s Update on the Combination of Umbralisib, Ublituximab, and Venetoclax for Treatment of CLL
- TG Therapeutics Announces Positive Topline Results from the UNITY-CLL Phase 3 Study Evaluating the Combination of Umbralisib and Ublituximab (U2) for the Treatment of Patients with CLL
CLL Society’s COVID-19 Virtual Community Meeting
Join us on Friday, September 24th for our continuing series, providing information to empower our CLL patient and caregiver community to make safe and informed decisions. CLL patients and caregivers can engage in a question-and-answer town hall format with a panel comprised of two CLL experts, an infectious disease specialist, and a virologist to discuss the current COVID-19 challenges affecting CLL patients. Register here.
The LLS Co-Pay Assistance Program offers financial assistance up to $8,000 for treatment-related expenses for eligible U.S. patients whether they are in active treatment, being monitored for watch and wait, or are in follow up care. This program can re-imburse medical insurance premiums, as well as cover non-diagnostic scans, lab work and testing, ECGs, EKGs, x-rays, ultrasounds, MRI, PET & CT scans, blood work, biopsies, bone marrow aspirations, tissue typing & stem cell harvesting for transplants, etc. Prescribed medications that can be covered including chemotherapy (IV or Oral) and supportive medications like anti-nausea, antibiotics, steroids, pain medication, and more. Apply now!
Ryan Mitchell’s Bike Ride for CLL Society!
We want to give a huge thank you to Ryan Mitchell who turned his participation in a bike ride on August 15th into a fundraiser for CLL Society! He raised $4,500 for those impacted by CLL. As Ryan said in his recap, he missed a turn in the route that resulted in an extra 9 miles added to the ride. But Ryan didn’t quit and finished strong to support CLL patients like him. Thank you, Ryan!
If you are interested in hosting your own fundraiser for CLL Society, please reach out to us at email@example.com.
Blood Cancer Awareness Month
September is Blood Cancer Awareness Month. Throughout the month, CLL Society will be active on social media to raise awareness and increase education for all impacted by CLL. As part of this effort, we want to elevate your voices. If you would like to provide a personal quote or story for CLL Society to post on our Facebook and/or Twitter please click here.
CLL Society Support Group Meetings Coming Up!
CLL Society Support Group meetings have moved to a virtual platform for most locations due to the threat of coronavirus. Support group members will receive an invitation to register for the meeting from the support group facilitator. If you are new to the group, please contact the RSVP email for the Support Group in your region. Once it is safe again, we will resume in-person meetings.
Visit the individual event listings on our website for the most up-to-date information on all CLL Society Support Group meetings.